Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
Thomas E. Witzig(WinnMed), Antonio Gualberto(Kura Oncology (United States)), Raquel De Oña Navarrete(MD Anderson Cancer Center Madrid), Robert C. Curry(Kura Oncology (United States)), Antonia Rodríguez Izquierdo(Hospital Universitario 12 De Octubre), Lubomir Sokol(Moffitt Cancer Center), Francine M. Foss(Yale Cancer Center), Jose Maria Roncero Vidal(Institut Català d'Oncologia), Ranjana H. Advani(Stanford Medicine), Catherine Scholz(Kura Oncology (United States)), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Eric D. Jacobsen(Dana-Farber Cancer Institute), R. Mondéjar(Hospital Universitario Fundación Jiménez Díaz), Won-Seog Kim(Samsung Medical Center), Fátima de la Cruz Vicente(Instituto de Biomedicina de Sevilla), Dolores Caballero(Complejo Hospitalario de Salamanca), Ana Marín‐Niebla(Vall d'Hebron Hospital Universitari)
Cited by 2
Related Papers
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|New England Journal of Medicine|2018|1.1k